Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMicrosaic Regulatory News (MSYS)

  • There is currently no data for MSYS

Manufacturing Services Framework Agreement

19 Apr 2022 07:00

RNS Number : 5035I
Microsaic Systems plc
19 April 2022
 

19 April 2022

 

Microsaic Systems PLC

 

("Microsaic" or "the Company")

Microsaic signs new manufacturing services frameworkand an initial contract worth £400k with Innovenn UK Limited

Microsaic now supplying services for Multi-Sensor Upgradesof Environmental and Human Health Diagnostic Equipment

 

Microsaic plc (AIM: MSYS) has signed a new framework agreement with, and an initial contract worth £400,000 from, Innovenn UK Limited, a division of DeepVerge plc ("DeepVerge"), to refine and miniaturise existing monitoring equipment for environmental and human health diagnostics (the "Manufacturing Services Framework Agreement" or "MSFA").

 

The MSFA framework sets out the terms and conditions for Microsaic to improve and manufacture certain DeepVerge products and to provide the design, assembly, quality, and project management functions necessary to produce and ship equipment based on DeepVerge approved specifications, design, and quality requirements.

 

The MSFA extends the parties' existing relationship which was formalised in the 3-year framework agreement announced on 24 March 2021[i], under which Microsaic supplies its own miniaturised mass spectrometry equipment and services on a non-exclusive basis across DeepVerge's global sales, marketing and distribution channels, for healthcare diagnostic and environmental health applications.1

 

Further manufacturing services contracts with DeepVerge may follow under the new MSFA, subject to satisfactory execution of the initial contract and mutual agreement.

 

The mutual goals under the MSFA include ensuring the timely availability of quality products and in the desired quantities, as well as meeting high workmanship and quality standards and ensuring delivery needs are met. Furthermore, DeepVerge and Microsaic will jointly strive to achieve value pricing consistent with prudent practices to balance costs and the availability of services materials.

 

Additional disclosure is made below in relation to AIM Rule 13.

 

Gerard Brandon, Acting Executive Chairman of Microsaic Systems plc, commented:

"Microsaic's business model has been transitioned to offer additional services which leverage the considerable depth and breadth of technical design, engineering and delivery expertise within its team. This new framework diversifies the Company's revenues beyond equipment sales of Mass Spectrometers. By offering the skillsets that created the smallest compact mass spectrometer in the world, partner customers such as DeepVerge can outsource their engineering development of existing and new monitoring equipment and concentrate on growing their business. This new agreement illustrates how Microsaic is able to access additional revenues from other innovative companies seeking a high quality product design, development and manufacturing service."

 

Microsaic Systems plc

Gerry Brandon, Acting Executive Chairman

 

+44 (0)734 0055 648

Singer Capital Markets(Nominated Adviser & Joint Broker)

+44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas 

 

 

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker / James Pope

+44 (0) 20 3657 0050

 

 

 

 

Related Party Transaction:

As set out above, an initial order for £400,000 has been placed in accordance with the terms of the MSFA under an agreed statement of work covering the specified supply of services and product. This new contract falls outside the scope of the existing framework agreement between the two companies.

 

The MSFA and the associated new order constitute a related party transaction for the Company under AIM Rule 13, as Microsaic directors Gerard Brandon (Acting Executive Chairman) and Nigel Burton (Non-executive Director) are also Executive Chairman and Non-executive Director, respectively, of DeepVerge.

 

The independent director (Robert Moore) considers, having consulted with Singer Capital Markets as the Company's nominated adviser, that the terms of MSFA and the associated new contract are fair and reasonable insofar as the Microsaic shareholders are concerned.

 

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

About Microsaic

Microsaic develops and commercialises micro-engineering chip-based mass spectrometry equipment. Microsaic has a robust patent portfolio in cutting-edge technology purpose built for "Industry 4.0" which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow, or in frontline environmental monitoring

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins; Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin.

 

 

[i] https://www.londonstockexchange.com/news-article/MSYS/framework-services-agreement-update/14911251 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTEAELPFDXAEAA
Date   Source Headline
24th Nov 20222:00 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
13th Sep 20227:25 amRNSSupply of mass spectroscopy services to DeepVerge
22nd Aug 20227:00 amRNSPartnership with Kingfield Electronics
5th Jul 20224:41 pmRNSSecond Price Monitoring Extn
5th Jul 20224:35 pmRNSPrice Monitoring Extension
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:01 pmRNSPrice Monitoring Extension
4th Jul 20224:43 pmRNSReplacement: Trading Update
1st Jul 20222:09 pmRNSHolding(s) in Company
30th Jun 202212:11 pmRNSResult of AGM
30th Jun 20227:00 amRNSTrading Update
1st Jun 20227:00 amRNSPosting of Annual Report & Notice of AGM
30th May 20227:00 amRNSFinal Results
19th Apr 20227:00 amRNSManufacturing Services Framework Agreement
28th Mar 20227:30 amRNSUpdate on Microsaic's miniaturised technology
15th Mar 20227:00 amRNSBoard Appointment and Strategic Update
8th Mar 20224:35 pmRNSPrice Monitoring Extension
7th Mar 20222:05 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
21st Feb 20221:31 pmRNSHolding(s) in Company
17th Feb 20222:45 pmRNSHolding(s) in Company
16th Feb 202211:06 amRNSSecond Price Monitoring Extn
16th Feb 202211:00 amRNSPrice Monitoring Extension
14th Feb 20227:00 amRNSDirector Dealing, Issue of Equity and TVR
28th Jan 20227:00 amRNSResignation of Chief Executive Officer
12th Jan 20224:43 pmRNSHolding(s) in Company
10th Jan 20223:30 pmRNSInvestor Presentation
10th Jan 20227:00 amRNSTrading Update
7th Jan 20222:06 pmRNSSecond Price Monitoring Extn
7th Jan 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSFurther order from DeepVerge
12th Nov 20217:00 amRNSNew compact screening platform
5th Nov 202110:12 amRNSHolding(s) in Company
27th Oct 20217:00 amRNSLaunch of technology for scaling drug manufacture
22nd Oct 20217:00 amRNSBoard Change
21st Oct 20217:00 amRNSUpdate on DeepVerge Collaboration
28th Sep 20214:30 pmRNSHolding(s) in Company
27th Sep 20217:00 amRNSInterim Results
24th Sep 20217:00 amRNSSigning of agreement to support China operations
22nd Sep 202111:06 amRNSNotice of Results and Investor Presentation
27th Aug 20214:40 pmRNSSecond Price Monitoring Extn
27th Aug 20214:35 pmRNSPrice Monitoring Extension
23rd Aug 20217:00 amRNSDeepVerge Collaboration for Water & Soil Analysis
9th Aug 20217:00 amRNSHeads of Terms signed with manufacturer in China
6th Jul 202111:55 amRNSInvestor Presentation
6th Jul 20217:00 amRNSTrading update for H1 2021
5th Jul 20219:50 amRNSHolding(s) in Company
2nd Jul 20217:00 amRNSDevelopment of real-time monitoring solution
17th Jun 202110:54 amRNSResult of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.